Clinical Trial Update: ALADDIN Study - Phase III: Antigonadotropin-Leuprolide in Alzheimer's Disease Drug INvestigation (VP-AD-301) [Phase 3]

View source ↗

Summary

The ALADDIN Phase III study VP-AD-301 evaluating leuprolide for Alzheimer's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Leuprolide (Leuprolide acetate)

Snippet

Sponsor: Voyager Pharmaceutical Corporation | Conditions: Alzheimer's Disease | Phase 3 | Status: COMPLETED